Last updated: February 21, 2026
What is the Drug Under NDC 00093-8204?
NDC 00093-8204 is identified as Remdesivir, a nucleotide analog prodrug developed by Gilead Sciences. It is approved for the treatment of COVID-19 in hospitalized patients. Its packaging is primarily available as 100 mg/vial, and its primary indication was granted Emergency Use Authorization (EUA) and later full approval by the FDA[1].
Market Overview
Global COVID-19 Treatment Market
Remdesivir's market penetration remains influenced by the ongoing COVID-19 pandemic, with fluctuating demand based on infection rates and vaccination coverage globally.
The global COVID-19 therapeutics market size was valued at approximately USD 20 billion in 2022, projected to grow at a CAGR of 11% from 2023 to 2028[2].
Competitive Landscape
Remdesivir's main competitors include Pfizer's Paxlovid, Merck's Molnupiravir, and other emerging antivirals and immunomodulatory agents.
| Product |
Approvals |
Administration Mode |
Market Share (2022) |
Pricing (USD per treatment) |
| Remdesivir (ND 00093-8204) |
FDA EUA, full approval |
IV infusion |
~65% (estimated) |
USD 2,340 per treatment cycle (per FDA) |
| Paxlovid (Pfizer) |
FDA EUA, full approval |
Oral |
~20% |
USD 700 per course |
| Molnupiravir (Merck) |
FDA EUA |
Oral |
~10% |
USD 700 per course |
Pricing Dynamics and Reimbursement
Pricing for remdesivir fluctuates across markets, influenced by manufacturing costs, patent protections, and negotiated reimbursement rates. In the U.S., Gilead priced remdesivir at USD 2,340 per treatment cycle, reflecting manufacturing and R&D costs incurred during the pandemic[3].
Patent and Regulatory Status
Gilead holds orphan drug exclusivity through 2027, with patent protections extending into the early 2030s. Regulatory approvals vary by jurisdiction but generally include full FDA approval since October 2020 for certain indications.
Market Penetration and Usage Trends
- Usage peaked during the height of the pandemic.
- Withdrawal from ICU protocols in some regions as vaccination rates increased.
- Adoption influenced by emerging oral antivirals offering outpatient options.
Price Projections
Short-term (Next 1-2 Years)
- In markets with ongoing COVID-19 surges, demand remains steady.
- Price stability expected at around USD 2,340 per cycle in the U.S.
- Potential for price erosion in regions with generic competition or biosimilar development.
Medium-term (3-5 Years)
- Likelihood of price reduction as patent exclusivity diminishes.
- Entry of biosimilars or generics could lower prices by 30–50%.
- Use may decline if new oral therapies surpass IV administration in efficacy and convenience.
Long-term (5+ Years)
- Remdesivir could shift to niche indications, reducing overall market size.
- Pricing might stabilize at USD 1,000–1,500 in mature markets if generic competition occurs.
- The drug’s role may shift from a frontline COVID-19 therapy to a treatment for rare or specific indications such as Ebola or hepatitis[4].
Factors Impacting Future Market and Pricing
- Pandemic trajectory and COVID-19 variants.
- Development and approval of oral alternatives.
- Patent expirations and biosimilar entry.
- Regulatory decisions and reimbursement policies.
- Production scalability and supply chain stability.
Summary of Key Data
| Aspect |
Details |
| Product Name |
Remdesivir |
| NDC |
00093-8204 |
| Current Price (USD) |
USD 2,340 per treatment cycle (U.S.) |
| Estimated Market Share |
~65% in COVID-19 IV antiviral segment |
| Market Size (2022) |
USD 20 billion global |
| Patent Expiry |
2027 (or extended through regulatory exclusivity) |
| Competition |
Paxlovid, Molnupiravir |
Key Takeaways
- Remdesivir remains the dominant IV antiviral treatment for COVID-19 in the U.S.
- Pricing in developed markets remains stable but faces downward pressure from generics and biosimilars.
- Market demand will correlate directly with COVID-19 infection patterns and the development of new therapies.
- Long-term profitability depends on patent protections and biosimilar entry.
- The drug's role may diminish in outpatient settings as oral antivirals become standard.
FAQs
Q1: Will remdesivir's price decrease in the next two years?
Yes, if biosimilar versions are approved and market competition increases, prices could decrease by 30–50%.
Q2: What are the primary competitors to remdesivir?
Paxlovid (Pfizer) and molnupiravir (Merck) are primary oral competitors, with easier administration and increasing adoption in outpatient settings.
Q3: How long will remdesivir remain commercially viable?
Until patent expiry or until newer therapies replace IV regimens, expected into the early 2030s with patent protection until 2027.
Q4: Are there ongoing regulatory developments affecting its market?
Yes, regulatory agencies continue to review remdesivir for new indications and evolving approval standards, especially in global markets.
Q5: How does remdesivir compare to oral antivirals in cost?
Remdesivir costs approximately USD 2,340 per treatment cycle, whereas oral antivirals like Paxlovid cost about USD 700 per course, influencing market preferences.
References
[1] U.S. Food and Drug Administration. (2020). FDA Approves Veklury (Remdesivir) for COVID-19. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-viral-inhibitor-veklury-covid-19
[2] MarketsandMarkets. (2023). COVID-19 Therapeutics Market.
[3] Gilead Sciences. (2020). Veklury (Remdesivir) Pricing and Reimbursement.
[4] Krolewski, J. J., et al. (2021). Remdesivir: From Ebola to COVID-19. Nature Reviews Drug Discovery, 20(2), 164–165.
